St. Jude expands strategic plan to target pediatric catastrophic diseases

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

In last week’s issue of The Cancer Letter, the cover story featured something special: The first de novo book published by The Cancer History Project. The book, “Backwater to Blockbuster: St. Jude Children’s Research Hospital,” co-written by Charles J. Sherr and William E. Evans, chronicles the previously untold story of St. Jude Children’s Research Hospital and its rise to becoming a global leader in pediatric cancer research.

May 20, 2026

In Brief

Northwestern Mutual to support childhood cancer survivors, siblings with $500,000 in college scholarships

Northwestern Mutual, through its Foundation, announced a class of scholars from its annual Childhood Cancer Scholarship Program for families affected by childhood cancer. The program provides scholarships to students affected by a diagnosis—either as survivors themselves or as siblings—enabling recipients to chase their dreams and transform their experience into purpose.

May 15, 2026

Vol.52 No.19

Drugs & Targets

EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration

The European Commission has granted conditional marketing authorization for Ojemda (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.

April 24, 2026

Vol.52 No.16

In Brief

James Downing to step down as president and CEO of St. Jude to focus on global pediatric medicine

After leading unprecedented growth of St. Jude Children’s Research Hospital over the past 12 years, James R. Downing will step down as president and CEO in late 2026 as part of a planned leadership transition, St. Jude officials said.

February 20, 2026

Vol.52 No.07

Clinical Roundup

NCCN guidelines detail fundamental differences between pediatric and adult cancers

The National Comprehensive Cancer Network published guidelines for Pediatric Soft Tissue Sarcoma. This is the 7th NCCN Guidelines for a pediatric cancer, expanding the overall library to cover 91 topics in cancer care.

February 20, 2026

Vol.52 No.07

Capitol Hill

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Sometime next week, the Senate is expected to vote on a legislative package that would determine the fiscal year 2026 spending levels for much of the federal government.

January 23, 2026

Vol.52 No.03

By Jacquelyn Cobb

St. Jude expands strategic plan to target pediatric catastrophic diseases

YOU MAY BE INTERESTED IN

The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue

Northwestern Mutual to support childhood cancer survivors, siblings with $500,000 in college scholarships

EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration

James Downing to step down as president and CEO of St. Jude to focus on global pediatric medicine

NCCN guidelines detail fundamental differences between pediatric and adult cancers

Fifth time’s a charm? Mikaela Naylon Give Kids a Chance Act is included in FY26 spending bill

Renew today!

Subscriber content

Never miss an issue!

Login